Wall Street Zen Downgrades Tenax Therapeutics (NASDAQ:TENX) to Strong Sell

Posted by Brenda Bartman on Aug 17th, 2026

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Several other research analysts have also weighed in on the company. Roth Capital set a $5.00 price objective on Tenax Therapeutics in a research report on Monday, August 10th. Guggenheim set a $4.00 target price on Tenax Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 11th. William Blair lowered Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 10th. Canaccord Genuity Group set a $4.00 price target on Tenax Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Piper Sandler raised their price objective on Tenax Therapeutics from $20.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, June 12th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.00.

Check Out Our Latest Analysis on TENX

Tenax Therapeutics Price Performance

NASDAQ:TENX opened at $1.80 on Friday. The company’s 50-day moving average is $12.85 and its two-hundred day moving average is $13.01. Tenax Therapeutics has a 1-year low of $1.31 and a 1-year high of $19.40. The firm has a market capitalization of $67.36 million, a price-to-earnings ratio of -1.22 and a beta of 0.93.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. As a group, equities analysts anticipate that Tenax Therapeutics will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter worth approximately $92,000. Letko Brosseau & Associates Inc. acquired a new stake in Tenax Therapeutics during the 4th quarter worth approximately $130,000. Corient Private Wealth LLC purchased a new position in Tenax Therapeutics in the 4th quarter valued at approximately $151,000. Quadrature Capital Ltd purchased a new position in Tenax Therapeutics in the 4th quarter valued at approximately $252,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Tenax Therapeutics in the fourth quarter worth $273,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.